NEW ZEALAND DATA SHEET  
OSPAMOX (AMOXICILLIN THIHYDRATE) POWDER FOR ORAL SUSPENSION  

1. PRODUCT NAME  
Amoxicillin Trihydrate dried suspension 125 mg/5 ml, 250 mg/5 ml and 100 mg/ml (as amoxicillin)  

2. QUALITATIVE AND QUANTITATIVE COMPOSITION  
Ospamox powder for oral suspension  
125 mg/5 ml: Reconstituted suspension contains in 5 ml, Amoxicillin Trihydrate Ph Eur equivalent to amoxicillin 125 mg.  
250 mg/5 ml: Reconstituted suspension contains in 5 ml, Amoxicillin Trihydrate Ph Eur equivalent to amoxicillin 250 mg.  
500 mg/5 ml: Reconstituted suspension contains in 5 ml, Amoxicillin Trihydrate Ph Eur equivalent to amoxicillin 500 mg.  

Ospamox Paediatric Drops 100 mg/ml  
Reconstituted suspension contains in 1 ml, Amoxicillin Trihydrate Ph Eur equivalent to amoxicillin 100 mg.  

For the full list of excipients, see Section 6.1.  

3. PHARMACEUTICAL FORM  
Ospamox powder for oral suspension  
125 mg/5 ml: Suspension, oral, powder for, white to yellowish colour.  
250 mg/5 ml: Suspension, oral, powder for, white to yellowish colour.  
500 mg/5 ml: Suspension, oral, powder for, white to yellowish colour.  

Ospamox Paediatric Drops 100 mg/ml  
Suspension, oral, granules for, white to yellowish colour.  

4. CLINICAL PARTICULARS  
4.1. THERAPEUTIC INDICATIONS  
Treatment of infection  
Ospamox is indicated in the treatment of infections due to susceptible organisms.  
Ospamox may be useful in instituting therapy prior to bacteriology; however, bacteriological studies to determine the causative organisms and their sensitivity to amoxicillin should be performed.  

Prophylaxis for endocarditis  
Ospamox may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis.
4.2. **DOSE AND METHOD OF ADMINISTRATION**

**Dosage**

*Upper respiratory tract infections, Genito-urinary tract infections, skin and soft tissue infections*

For upper respiratory tract infections due to streptococci, pneumococci, non-penicillinase-producing staphylococci and *H. influenzae* or Genito-Urinary Tract Infections (due to *Escherichia coli*, *Proteus mirabilis* and *Streptococcus faecalis* or Skin and Soft Tissue Infections due to streptococci, sensitive staphylococci and *Escherichia coli*):

- **Adults**: 250 mg every 8 hours.
- **Children (under 20 kg)**: 25 mg/kg/day in equally divided doses every 8 hours.

In severe infections or those caused by less susceptible organisms, 500 mg every 8 hours for adults and 50 mg/kg/day in equally divided doses every 8 hours for children may be needed.

*Lower respiratory tract infections*

For lower respiratory tract infections (due to streptococci, pneumococci, non-penicillinase producing staphylococci and *H. influenzae*):

- **Adults**: 500 mg every 8 hours.
- **Children (under 20 kg)**: 50 mg/kg/day in equally divided doses every 8 hours.

**High dosage therapy**

The maximum recommended oral dosage 6 g daily in divided doses. An adult dosage of 3 g twice daily is recommended in appropriate cases for the treatment of severe or recurrent purulent infection of the respiratory tract.

**Prophylaxis of Endocarditis - Dental Procedures**

Prophylaxis for patients undergoing extraction, scaling or surgery involving gingival tissues who have not received a penicillin in the previous month. Patients with prosthetic heart valves should be referred to hospital (see below).

**Patient not having a general anaesthetic**

Adults – 3 g orally, 1 hour before procedure. A second dose may be given 6 hours later if considered necessary. Children under 10 - half the adult dose. Children under 5 - quarter adult dose.

**Patients having a general anaesthetic, oral antibiotics considered to be appropriate**

Adults - initially 3 g orally 4 hours prior to anaesthesia followed by 3 g orally (or 1 g amoxicillin/amoxicillin IM if the dose is not tolerated) 6 hours after the initial dose.

Children under 10 - half adult dose.

Children under 5 - quarter adult dose.

**Patient having general anaesthesia, oral antibiotics not appropriate**

Adults – 1 g amoxicillin IM immediately before induction with 500 mg orally 6 hours later. Children under 10 - half adult dose.
Note: If prophylaxis with amoxicillin is given twice within one month, emergence of resistant streptococci is unlikely to be a problem. Alternatively, antibiotics are recommended if more frequent prophylaxis is required, or the patient has received a course of treatment with a penicillin during the previous month.

**Patients for whom referral to hospital is recommended**

- Patients to be given a general anaesthetic who have been given a penicillin in the previous month.
- Patients to be given a general anaesthetic who have a prosthetic heart valve.
- Patients who have had one or more attacks of endocarditis.

Adults - Initially 1 g amoxicillin/ampicillin with 120 mg gentamicin IM immediately prior to anaesthesia (if given) or 15 minutes prior to dental procedure, followed by 500 mg Ospamox orally, 6 hours later.

Children under 10 - the dose of amoxicillin should be half the adult dose. The dose of gentamicin should be 2 mg/kg.

Note: Amoxicillin and gentamicin should not be mixed in the same syringe. Please consult the appropriate Data Sheet for parenteral amoxicillin and gentamicin.

**Urethritis (due to Neisseria gonorrhoeae)**

Adults: 3 g, as single dose. Cases of gonorrhoea with a suspected lesion of syphilis should have dark field examinations before receiving amoxicillin and monthly serological tests for a minimum of four months.

**Lower urinary tract infections**

For acute, uncomplicated lower urinary tract infections (due to *Escherichia coli*, *Proteus mirabilis*, *Streptococcus faecalis*, non-penicillinase producing staphylococci):

Adults: 3 g as a single dose.

NOTE: The children's dose is intended for individuals whose weight will not cause dosage to be calculated greater than that recommended for adults. Children weighing more than 20 kg should be dosed according to the adult recommendations.

It should be recognised that in the treatment of chronic urinary tract infections, frequent bacteriological and clinical appraisals are necessary. Smaller doses than those recommended above should not be used. In stubborn infections, therapy may be required for several weeks. It may be necessary to continue clinical and/or bacteriological follow-up for several months after cessation of therapy.

**Treatment duration**

Treatment should be continued for a minimum of 48 to 72 hours beyond the time that the patient becomes asymptomatic or evidence of bacterial eradication has been obtained.

It is recommended that there be at least 10 days treatment for any infection caused by haemolytic streptococci to prevent the occurrence of rheumatic fever or glomerulonephritis.

**Dosage adjustment in:**

- renal impairment
In renal impairment, the excretion of amoxicillin will be delayed. Depending on the degree of
impairment, it may be necessary to reduce the total daily dosage. No dosage adjustment is
required in patients with a creatinine clearance > 30 ml/min. The maximum recommended dose
in patients with creatinine clearance between 10 and 30 ml/min is 500 mg twice daily. The
maximum recommended dose in patients with a creatinine clearance < 10 ml/min is 500
mg/day.

In patients receiving peritoneal dialysis, the maximum recommended dose is 500 mg/day.
Amoxicillin may be removed from the circulation by haemodialysis.

**Renal impairment in children under 40 kg**

- Creatinine clearance >30 ml/min: No adjustment necessary
- Creatinine clearance 10 to 30 ml/min: 15 mg/kg given twice daily (maximum 500 mg/twice
daily)
- Creatinine clearance <10 ml/min: 15 mg/kg given as a single daily dose (maximum 500 mg)

In the majority of cases, parenteral therapy will be preferred.

### 4.3. Contraindications

Amoxicillin is a penicillin and should not be given to patients with a history of hypersensitivity
to beta-lactam antibiotics (e.g. penicillins, cephalosporins, carbapenem or monbactam).
Potential cross allergy to other beta-lactams such as cephalosporins should be taken into
account.

Known and suspected hypersensitivity to the active substance, to any of the penicillins or
known hypersensitivity to any of the excipients.

Antibiotics have no place in trivial infections

### 4.4. Special Warnings and Precautions for Use

**Warnings**

Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been
reported in patients receiving beta-lactam antibiotics. Although anaphylaxis is more frequent
following parenteral therapy, it has occurred in patients on oral therapy. Before initiating
therapy with amoxicillin, careful enquiry should be made concerning previous hypersensitivity
reactions to penicillins, cephalosporins. Cross-sensitivity between penicillins and
cephalosporins is well documented. Patients should be told about the potential occurrence of
allergic reactions and instructed to report them. If an allergic reaction occurs, amoxicillin
should be discontinued and appropriate alternative therapy instituted. Patients should be told
about the potential occurrence of allergic reactions and instructed to report them.

Serious anaphylactic reactions may require immediate emergency treatment with adrenaline or
epinephrine. Oxygen, intravenous steroids and airway management, including intubation, may
also be required. Amoxicillin should be given with caution to patients with lymphatic
leukaemia, as they are susceptible to amoxicillin induced skin rashes.

Amoxicillin is not suitable for the treatment of some types of infection unless the pathogen is
already documented and known to be susceptible or there is a very high likelihood that the
pathogen would be suitable for treatment with amoxicillin. This particularly applies when
considering the treatment of patients with urinary tract infections and severe infections of the
ear, nose and throat.
Amoxicillin, an aminopenicillin, is not the treatment of choice in patients presenting with sore throat or pharyngitis because of the possibility that the underlying cause is infectious mononucleosis, in the presence of which there is a high incidence of rash if amoxicillin is used. Prolonged use may occasionally result in overgrowth of non-susceptible organisms.

Antibiotic associated pseudomembranous colitis has been reported with many antibiotics including amoxicillin. A toxin produced by *Clostridium difficile* appears to be the primary cause. The severity of the colitis may range from mild to life threatening. It is important to consider this diagnosis in patients who develop diarrhoea or colitis in association with antibiotic use (this may occur up to several weeks after cessation of antibiotic therapy). If prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further. Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases appropriate therapy with a suitable oral antibacterial agent effective against *Clostridium difficile* should be considered. Fluids, electrolytes and protein replacement should be provided when indicated. Drugs which delay peristalsis e.g. opiates and diphenoxylate with atropine (Lomotil) may prolong and/or worsen the conditions and should not be used.

Amoxicillin should not be used for the treatment of bacterial infections in patients with viral infections, presenting with sore throat, pharyngitis or infectious mononucleosis, as a high incidence of amoxicillin induced erythematous (morbilliform) rashes have been associated with glandular fever in patients receiving amoxicillin.

As with any potent drug, periodic assessment of renal, hepatic and haematopoietic function should be made during prolonged therapy. Elevated liver enzymes and changes in blood counts have been reported. Prolonged use may occasionally result in overgrowth of non-susceptible organisms. The possibility of superinfection with mycotic or bacterial pathogens should be particularly considered. If superinfection occurs (usually involving Aerobacter, *Pseudomonas* or *Candida*) discontinue amoxicillin and/or initiate appropriate therapy.

The Jarisch-Herxheimer reaction has been seen following amoxicillin treatment of Lyme disease. It results directly from the bactericidal activity of amoxicillin on the causative bacteria of Lyme disease, the spirochaete Borrelia burgdorferi. Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease.

Pseudomembranous colitis should be borne in mind if severe persistent diarrhoea occurs (in most cases caused by *Clostridium difficile*). In this case Amoxicillin should be discontinued and an adequate therapy has to be started. The use of antiperistaltics is contraindicated.

Abnormal prolongation of prothrombin time has been reported rarely in patients receiving amoxicillin and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulation treatment is prescribed concurrently and the dose of the anticoagulant adjusted as necessary.

In patients with reduced urine output crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria (refer to Section 4.9 Overdose). The presence of high urinary concentrations of amoxicillin can cause precipitation of the product in urinary catheters. Therefore, catheters should be visually inspected at intervals. At high doses, adequate fluid intake and urinary output must be maintained to minimise the possibility of amoxicillin crystalluria.
Precaution should be taken in premature children and during neonatal period: renal, hepatic and haematological functions should be monitored.

As with other beta-lactams, the blood formula should be checked regularly during high-dose therapy.

High dose therapy with beta-lactams for patients with renal insufficiency or seizures history, treated epilepsy and meningeal affection, could exceptionally lead to seizures.

The occurrence of a generalized erythema with fever and pustules at the beginning of treatment should make suspect a generalized acute exanthematic pustulosis; this necessitates the interruption of therapy and contraindicated any further administration of amoxicillin.

Amoxicillin should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.

**Precautions**

Following single dose therapy of acute lower urinary tract infections, the urine should be cultured. A positive culture may be evidence of a complicated or upper urinary tract infection, and higher dose or prolonged course of treatment may be appropriate.

Patients suffering from severe gastrointestinal disturbances with diarrhoea and vomiting should not be treated with Ospamox, due to the risk of reduced absorption. In these cases, a parenteral treatment with amoxicillin is advisable.

Ospamox should be used with caution in patients with allergic diathesis and asthma.

Ospamox Suspensions, which contain aspartame, should be used with caution in patients with phenylketonuria.

Ospamox Paediatric Drops contain sucrose and saccharin sodium as sweeteners.

Ospamox Powder for Oral Suspension and Ospamox Paediatric Drops contain sodium benzoate.

**Use in renal impairment**

Dosage should be adjusted in patients with renal impairment (refer to Section 4.2 Dose and method of administration).

**Use in the elderly**

No data available.

**Paediatric use**

Precaution should be taken in premature children and during neonatal period: renal, hepatic and haematological functions should be monitored.

**Effects on laboratory tests**

At high risk concentrations, amoxicillin may diminish the results of serum glycaemia levels. It is recommended that when testing for the presence of glucose in urine during amoxicillin treatment, enzymatic glucose oxidase methods should be used. Due to the high urinary concentrations of amoxicillin, false positive readings are common with chemical methods.
Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone and estradiol has been noted. This effect may also occur with amoxicillin.

Amoxicillin may interfere with protein testing when colorimetric methods are used.

4.5. INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Medicines and other pharmacologically active substances

Concurrent administration of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.

Concomitant administration of amoxicillin and anticoagulants, such as coumarin, may increase the incidence of bleeding due to prolongation of prothrombin time. Appropriate monitoring should be undertaken when anticoagulation treatment is prescribed concurrently and the dose of the anticoagulant adjusted as necessary. A large number of cases showing an increase of oral anticoagulant activity has been reported in patients receiving antibiotics. The infectious and inflammatory context, age and the general status of the patient appear as risk factors. In these circumstances, it is difficult to know the part of the responsibility between the infectious disease and its treatment in the occurrence of INR disorders. However, some classes of antibiotics are more involved, notably fluoroquinolones, macrolides, cyclines, cotrimoxazole and some cephalosporins.

There is a possibility that the bactericidal action of amoxicillin could be antagonised on co-administration with bacteriostatic agents such as macrolides, tetracyclines, sulphonamides or chloramphenicol.

An increase in the absorption of digoxin is possible on concurrent administration with amoxicillin. A dose adjustment of digoxin may be necessary.

Interaction between amoxicillin and methotrexate leading to methotrexate toxicity has been reported. Serum methotrexate levels should be closely monitored in patients who receive amoxicillin and methotrexate simultaneously. Amoxicillin decreases the renal clearance of methotrexate, probably by competition at the common tubular secretion system.

Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with amoxicillin may result in increased and prolonged levels of amoxicillin in serum and bile.

Administration of amoxicillin can transiently decrease the plasma level of estrogens and progesterone, and may reduce the efficacy of oral contraceptives. It is therefore recommended to take supplemental non-hormonal contraceptive measures.

Forced diuresis leads to a reduction in blood concentrations by increased elimination of amoxicillin.

It is recommended that when testing for the presence of glucose in urine during amoxicillin treatment, enzymatic glucose oxidase methods should be used. Due to the high urinary concentrations of amoxicillin, false positive readings are common with chemical methods.

The occurrence of diarrhoea may impair the absorption of other medicines consequently limiting their efficacy.

Amoxicillin may decrease the amount of urinary estriol in pregnant women.
At high concentrations, amoxicillin may diminish the results of serum glycemia levels.

Amoxicillin may interfere with protein testing when colormetric methods are used.

4.6. FERTILITY, PREGNANCY AND LACTATION

Effects on fertility
Reproduction studies have been performed in mice and rats at doses up to ten times the human dose and these studies have revealed no evidence of impaired fertility or harm to the foetus due to amoxicillin.

Use in pregnancy
Category A

Assigned Category A by the Australian Drug Evaluation Committee. This category includes medicines, which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the foetus having been observed. The safety of amoxicillin for use in human pregnancy has not been established by well controlled studies in pregnant women. Amoxicillin may be used in pregnancy when the potential benefits outweigh the potential risks associated with treatment.

Use in labour and delivery
Oral ampicillin class antibiotics are generally poorly absorbed during labour. Studies in guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency and duration of contractions. However, it is not known whether the use of amoxicillin in humans during labour or delivery has immediate or delayed adverse effects on the foetus, prolongs the duration of labour or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.

Use in lactation
Residual amoxicillin may be present in breast milk at levels corresponding to approximately 0.7% of the maternal dose. Penicillins are considered to be compatible with breastfeeding although there are theoretical risks of alterations to infant bowel flora and allergic sensitisation. So far, no detrimental effects for the breast-fed infant have been reported after taking amoxicillin. Amoxicillin can be used during breast-feeding. However, breast-feeding must be stopped if gastrointestinal disorders (diarrhoea, candidosis or skin rash) occur in the newborn.

4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

This medicine is presumed to be safe or unlikely to produce an effect. However, undesirable effects may occur (e.g. allergic reactions, dizziness, convulsions), which may influence the ability to drive and use machines (see Section 4.8 Adverse effects (Undesirable effects)).

4.8. UNDESIRABLE EFFECTS

Side-effects, as with other penicillins, are uncommon and mainly of a mild and transitory nature. The majority of the side-effects listed below are not unique to amoxicillin and may occur when using other penicillins.
Undesirable effects are classified systematically and by frequency according to the following convention: very common (above 1 in 10); common (from 1 in 100 to 1 in 10); uncommon (from 1 in 1000 to 1 in 100; rare (from 1 in 10,000 to 1 in 1,000); very rare (below 1 in 10,000).

Unless otherwise stated, the frequency of adverse events has been derived from more than 30 years of post-marketing reports.

**Haemic and the lymphatic system disorders**

*Very rare*

Reactions such as anaemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia and leucopenia (including severe neutropenia or agranulocytosis), have been reported during therapy with other penicillins. All were reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. Prolongation of bleeding time and prothrombin time have also been reported rarely (refer to Section 4.4 Special warnings and precautions for use).

**Immune system disorders**

*Very rare*

As with other antibiotics, severe allergic reactions, including angioneurotic oedema, anaphylaxis (refer to Section 4.4 Special warnings and precautions for use), serum sickness and allergic vasculitis. If a hypersensitivity reaction is reported, the treatment must be discontinued. (See also Skin and subcutaneous tissue disorders).

**Infections and infestations**

*Uncommon*

Prolonged and repeated use of the preparation can result in superinfections and colonisation with resistant organisms or yeasts such as oral and vaginal candidiasis.

**Gastrointestinal disorders**

*Common*

Gastric complaints, nausea, loss of appetite, flatulence, soft stools, diarrhoea, enanthemas (particularly in the region of the mouth), dry mouth, taste disturbances. These effects on the gastrointestinal system are mostly mild and frequently disappear either during the treatment or very soon after completion of therapy. The occurrence of these side effects can generally be reduced by taking amoxicillin during meals.

*Uncommon*

Vomiting.

*Rare*

Superficial discoloration of the teeth (especially with the suspension). Usually the discoloration can be removed by teeth brushing.

*Very rare*

Mucocutaneous candidiasis. Antibiotic associated colitis including pseudomembranous colitis and haemorrhagic colitis. If severe and persistent diarrhoea occurs, the very rare possibility of
pseudomembranous colitis should be considered. The administration of anti-peristaltic agents is contraindicated.

Development of a black hairy tongue.

**General disorders and administration site conditions**

Rare

Drug fever

**Hepatobiliary disorders**

Rare

Hepatitis and cholestatic jaundice.

Uncommon

Moderate and transient increase of liver enzymes. The significance of a rise in liver enzymes is unclear

**Nervous system disorders**

Rare

Hyperkinesia, dizziness and convulsions. Convulsions may occur in patients with impaired renal function, epilepsy meningitis, or in those receiving high doses.

**Skin and subcutaneous tissue disorders**

Common

Cutaneous reactions such as exanthema, pruritus, urticaria, erythematous maculopapular rash; the typical morbilliform exanthema occurs 5 to 11 days after commencement of therapy. The immediate appearance of urticaria indicates an allergic reaction to amoxicillin and therapy should therefore be discontinued. Note urticaria, other skin rashes and serum sickness-like reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids.

Rare

Skin reactions such as Angioneurotic oedema (Quincke's oedema, erythema multiforme exudativum, exsudativum, acute generalized pustulosis, Lyell’s syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous and exfoliative dermatitis and acute generalised exanthematous pustulosis, Jarisch-Herxheimer reaction (see also Immune system disorders).

**Renal and urinary tract disorders**

Rare

Interstitial nephritis, crystalluria (refer to Section 4.9 Overdose)

The incidence of these adverse events was derived from clinical studies involving a total of approximately 6,000 adult and paediatric patients taking amoxicillin.
Reporting suspected adverse effects

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/

4.9. OVERDOSE

Signs and symptoms

Cases of overdosage with amoxicillin are usually asymptomatic. Gastrointestinal disturbances such as nausea, vomiting and diarrhoea and symptoms of fluid-electrolyte imbalance may be evident. In patients with severely impaired renal function, large overdoses can result in signs of renal toxicity and crystalluria is possible. During the administration of high doses of amoxicillin, adequate fluid intake and urinary output must be maintained to minimise the possibility of amoxicillin crystalluria.

Management

There is no specific antidote for an overdose of amoxicillin. Treatment consists primarily of administration of activated charcoal (a gastric lavage is usually not necessary), or symptomatic and supportive measures. Particular attention should be directed to the water and electrolyte balance of the patient. Amoxicillin can be removed from the circulation by haemodialysis.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. PHARMACOLOGICAL PROPERTIES

5.1. PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group

J01CA04 – Penicillins with extended spectrum, amoxicillin.

Pharmacodynamic effects

Inhibition of bacterial cell wall synthesis.

Antibiotic class

Amoxicillin is a semi-synthetic aminopenicillin of the beta-lactam group of antibiotics.

Mechanism of action

Beta-lactam antibiotic.

Amoxicillin is an aminobenzyl penicillin that has a bactericidal action due to its inhibition of the synthesis of the bacterial cell wall. It exerts a bactericidal effect against many Gram-positive and Gram-negative microorganisms. Amoxicillin is not effective against beta-lactamase producing organisms.

Antibiotic nature and mode of action

Amoxicillin has a broad spectrum of antibacterial activity against many Gram-positive and Gram-negative microorganisms, acting through the inhibition of biosynthesis of cell wall mucopenteide. Amoxicillin is active in vitro against beta-lactamase negative strains of *Proteus mirabilis*, and *Haemophilus influenza*. In vitro studies have also demonstrated activity against
most strains of alpha- and beta-haemolytic streptococci. *Streptococcus pneumoniae*, and betalactamase negative strains of staphylococci, *Neisseria gonorrhoeae*, *Neisseria meningitidis* and *Enterococcus faecalis*. However, some of the organisms are sensitive to amoxicillin only at concentrations achieved in the urine. Strains of gonococci, which are relatively resistant to benzyl penicillin, may also be resistant to amoxicillin.

Amoxicillin is susceptible to degradation by beta-lactamases and therefore it is ineffective against bacteria which produce these enzymes particularly resistant staphylococci, which now have a high prevalence. All strains of *Pseudomonas*, *Klebsiella* and *Enterobacter*, indole positive Proteus, *Serratia marcescens*, Citrobacter, penicillinase producing *N. gonorrhoeae* and penicillinase producing *H. influenzae* are also resistant. *Escherichia coli* isolates are becoming increasingly resistant to amoxicillin *in vitro* due to the presence of penicilllinase-producing strains.

**Susceptibility**

The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

**Breakpoints**

The MIC breakpoints for susceptible organisms vary according to species. Enterobacteriaceae are considered susceptible when inhibited at NMT 8 mcg/ml amoxicillin and resistant at NLT 32 mcg/ml.

From NCCLS recommendations and using NCCLS-specified methods, *M. catarrhalis* (beta-lactamase negative) and *H. influenzae* (beta-lactamase negative) are considered susceptible at NMT 1 mcg/ml and resistant at NLT 4 mcg/ml; *Str. pneumoniae* are considered susceptible to amoxicillin at MIC NMT 2 mcg/ml and resistant at NLT 8 mcg/ml.

**Susceptibility data**

Strains of the following named organisms are generally sensitive to the bactericidal action of amoxicillin *in vitro*.

Susceptible Gram-positive aerobes include *Enterococcus faecalis* (Note 2), *Streptococcus pneumoniae* (Notes 1, 3), *Streptococcus pyogenes* (Notes 1, 3), *Streptococcus viridans* (Note 2), *Streptococcus agalactiae*, *Streptococcus bovis*, *Staphylococcus aureus* (penicillin sensitive), *Corynebacterium* species (Note 2), *Bacillus anthracis*, *Listeria monocytogenes*.

Susceptible Gram-negative aerobes include *Haemophilus influenzae* (Note 3), *Haemophilus parainfluenzae* (Note 3), *Escherichia coli* (Note 3), *Proteus mirabilis*, *Salmonella* species (Note 2), *Shigella* species (Note 2), *Bordetella pertussis*, *Brucella* species (Note 1), *Neisseria gonorrhoeae* (Note 2), *Neisseria meningitidis* (Note 1), *Pasteurella septica*, *Helicobacter pylori*, *Leptospira* spp, *Vibrio Cholerae*  

Susceptible anaerobes include *Bacteroides melaninogenicus* (Note 2), *Clostridium* species, *Fusobacterium* spp. (Note 2), *Peptostreptococci*

Other susceptible organisms include *Borrelia burgdorferi*.

Note 1: No beta-lactamase producers have as yet been reported for these bacterial species.
Note 2: Inconstantly susceptible; susceptibility is therefore unpredictable in the absence of
susceptibility testing.
Note 3: Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications.

**Resistance**

Bacteria may be resistant to amoxicillin due to production of beta-lactamases, which hydrolyse aminopenicillins, due to alteration in penicillin-binding proteins, due to impermeability to the drug, or due to drug efflux pumps. One or more of these mechanisms may co-exist in the same organism, leading to a variable and unpredictable cross-resistance to other beta-lactams and to antibacterial drugs of other classes.

Resistant Gram-positive aerobes include *Staphylococcus* (beta-lactamase producing strains).


Resistant anaerobes include: *Bacteroides fragilis*.

Other resistant organisms include: *Chlamydia*, *Mycoplasma*, *Rickettsia*.

**Clinical trials**

No data available.

5.2. **PHARMACOKINETIC PROPERTIES**

**Absorption**

Amoxicillin is stable in the presence of gastric acid and rapidly absorbed from the gut to an extent of 72 to 93%. Absorption is independent of food intake. Peak blood levels are achieved 1 to 2 hours after administration. After 250 and 500 mg doses of amoxicillin, average peak serum concentrations of 5.2 mcg/ml and 8.3 mcg/ml respectively have been reported.

**Distribution**

Amoxicillin is not highly protein bound. Approximately 18% of total plasma drug content is bound to protein. Amoxicillin diffuses readily into most body tissues and fluids, including sputum and saliva but not the brain and spinal fluid. Inflammation generally increases the permeability of the meninges to penicillins and this may apply to amoxicillin. Amoxicillin diffuses across the placenta and a small percentage is excreted into the breast milk.

**Metabolism**

Amoxicillin is excreted mainly via the urine where it exists in a high concentration. Amoxicillin is also partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to 10 to 25% of the initial dose. Small amounts of the drug are also excreted in faeces and bile. Concentrations in the bile may vary and are dependent upon normal biliary function.

**Excretion**

Approximately 60 to 70% of amoxicillin is excreted unchanged in urine during the first 6 hours after administration of a standard dose. The elimination half-life is approximately 1 hour. Concurrent administration of probenecid delays amoxicillin excretion. In patients with end-stage renal failure, the half-life ranges between 5 to 20 hours. The substance is haemodialysable.
5.3. **Preclinical Safety Data**

**Genotoxicity**
No data available.

**Carcinogenicity**
No data available.

6. **Pharmaceutical Particulars**

6.1. **List of Excipients**

**Ospamox powder for oral suspension**
Guar gum, aspartame, citric acid anhydrous, sodium benzoate, talc, trisodium citrate anhydrous, colloidal anhydrous silica, lemon flavour, orange flavour, peach-apricot flavour.

**Ospamox Paediatric Drops**
Sucrose, trisodium citrate anhydrous, sodium benzoate, simethicone, guar gum, saccharin sodium, strawberry flavour, raspberry flavour, passion fruit flavour.

6.2. **Incompatibilities**
None known.

6.3. **Shelf Life**
24 months, store below 25°C.

6.4. **Special Precautions for Storage**

**Ospamox capsules**
Store at or below 25°C. Protect from moisture.

**Ospamox powder for oral suspension**
Store at or below 25°C. Protect from moisture.

**Ospamox Paediatric Drops**
Store at or below 25°C. Protect from light. Protect from moisture.

6.5. **Nature and Contents of Container**

**Ospamox powder for oral suspension**
125 mg/5 ml: Bottle of 100 ml.
250 mg/5 ml: Bottle of 100 ml.
500 mg/5 ml: Bottle of 100 ml.

**Ospamox Paediatric Drops 100 mg/ml**
Bottle of 30 ml with graduated dosing syringe.

*Not all pack sizes and/or strengths may be currently marketed.*
6.6. SPECIAL PRECAUTIONS FOR DISPOSAL

Instructions for use/handling

Reconstitution instructions for Ospamox powder for oral suspension
125 mg/5 ml: Add 94 ml of water to make up 100 ml.
250 mg/5 ml: Add 92 ml of water to make up 100 ml.

Close and shake well at once. Shake well before use. Store the reconstituted suspension at 2°C – 8°C (refrigerate) and use within 14 days of preparation.

Reconstitution instructions for Ospamox Paediatric Drops
100 mg/ml: Add 16 ml of water to make up 30 ml. Close and shake well at once. Shake well before use. Store the reconstituted suspension below 25°C and use within 14 days of preparation.

Any unused medicine or waste material should be disposed of in accordance with local requirements.

7. MEDICINE SCHEDULE

Prescription Only Medicine

8. SPONSOR
Novartis New Zealand Limited
PO Box 99102
Newmarket
AUCKLAND 1149
Telephone: 0800 354 335

9. DATE OF FIRST APPROVAL
30 September 2015

10. DATE OF REVISION OF THE TEXT
07 March 2019

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Revised to new format</td>
</tr>
<tr>
<td>4.3</td>
<td>Additional information of potential cross allergy to other beta-lactams</td>
</tr>
<tr>
<td>4.4</td>
<td>Addition of Jarisch-Herxheimer reaction</td>
</tr>
<tr>
<td></td>
<td>Addition of prolong use and infectious mononucleosis</td>
</tr>
<tr>
<td>4.7</td>
<td>Additional information of effects on ability to drive and use machines</td>
</tr>
<tr>
<td>4.8</td>
<td>Addition of Jarisch-Herxheimer reaction as a rare undesirable effect</td>
</tr>
</tbody>
</table>